Speclipse's Acquisition

Speclipse was acquired by CELLRETURN and Lindeman Asia Investment on November 05, 2019.

Speclipse develops technology for real-time, non-invasive, in-vivo cancer diagnosis utilizing laser spectroscopy and machining learning algorithms. The company's Spectra-Scope, available as either a s…

Articles about Speclipse's Acquisition: